Vistagen Therapeutics Inc — Quarterly Cash Flow (NASDAQ:VTGN) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 92.31 M84.34 M68.92 M80.93 M65.06 M Total liabilities 11.19 M13.95 M12.16 M14.59 M14.14 M Total equity 81.12 M70.39 M56.77 M66.34 M50.92 M Total liabilities & shareholders' equities 92.31 M84.34 M68.92 M80.93 M65.06 M Total debt ————— Net debt —————

Haberler

Vistagen Therapeutics maliyetleri yönetmek için işgücünü yüzde 20 azaltıyor

Vistagen Therapeutics reduces workforce by 20 percent to manage costs

VistaGen TD Cowen Konferansı: Pherine Platformu Odakta

VistaGen at TD Cowen Conference: Pherine Platform in Focus

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

VistaGen Therapeutics’in 2026 3. Çeyrek Kazanç Görüşmesi Yapay Zeka Destekli Deneme Analizini Vurguluyor

Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

Vistagen Therapeutics’in fasedienol için Faz 3 deneyi sonuç hedefine ulaşamadı

Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%

Jefferies, başarısız Faz III denemesi sonrası VistaGen hisse derecelendirmesini Tut’a düşürdü